Loading
AEWS0031 showed that giving the same chemotherapy for Ewing sarcoma every two weeks instead of every three cured more patients without adding side effects, and the two-weekly schedule became the standard for localised disease in North America.
AEWS0031 was a Children's Oncology Group phase 3 trial that randomised 587 patients (568 eligible, 284 per arm) with localised Ewing sarcoma to fourteen cycles of alternating vincristine, doxorubicin, cyclophosphamide and ifosfamide, etoposide given every 21 days or every 14 days with growth factor support. The primary endpoint was event-free survival.
The median cycle interval achieved was 21 days in the standard arm and 15 days in the intensified arm. Event-free survival at five years was 73 percent with interval compression against 65 percent with the standard schedule, with similar toxicity. Interval-compressed VDC/IE is the standard first-line regimen on the corpus's Ewing sarcoma page, alongside the European Euro Ewing 2012 result that reached the same conclusion.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
587 enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Event-free survival at 5 yearsprimary | Interval-compressed VDC/IE every 14 days | 284 | 73% | - | 0.048 | link |
| Standard VDC/IE every 21 days | 284 | 65% |
Shares Childhood cancers (all types), Vincristine, Etoposide, Doxorubicin and the tag soc-trials.
Shares Childhood cancers (all types), Children's Oncology Group (COG), Vincristine, Etoposide and the tag soc-trials.
Shares Childhood cancers (all types), Children's Oncology Group (COG), Vincristine, Etoposide and the tag soc-trials.
Shares Childhood cancers (all types), Children's Oncology Group (COG), Vincristine, Etoposide and the tag soc-trials.
Shares Childhood cancers (all types), Children's Oncology Group (COG), Etoposide, Doxorubicin and the tag soc-trials.
Shares Childhood cancers (all types), Children's Oncology Group (COG), Vincristine, Cyclophosphamide and the tag soc-trials.
Shares Ifosfamide, Childhood cancers (all types), Children's Oncology Group (COG), Etoposide and the tag soc-trials.
Shares Childhood cancers (all types), Children's Oncology Group (COG), Vincristine, Etoposide and the tag soc-trials.